Enliven Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Enliven Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($20.15M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($25.34M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($25.34M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($28.54M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($28.54M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($28.54M) | Nov 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($23.16M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($19.95M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($19.95M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($22.74M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($22.74M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($22.74M) | Nov 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($20.77M) | Nov 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($16.72M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.72M) | Aug 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($14.72M) | Aug 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($14.72M) | Nov 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.72M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.55M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($8.89M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($25.10M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($28.58M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($31.69M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($27.07M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($24.60M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($25.99M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($24.25M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.13M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.42M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.93M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.02M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($8.68M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($13.66M) | Oct 25, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($13.17M) | Aug 3, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($10.28M) | May 6, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($12.49M) | Nov 9, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($10.30M) | Aug 6, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.35M) | May 11, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($6.88M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($5.56M) | Aug 14, 2020 |